Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has accepted ...

Pharmaceuticals announced that the U.S. FDA has accepted the New Drug Application for investigational plozasiran for the ...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) said the FDA has accepted its New Drug Application for its drug plozasiran for the ...

Arrowhead Pharmaceuticals said Friday that the Food and Drug Administration accepted the company's new drug application for its treatment of familial chylomicronemia syndrome, a severe and rare ...

The voices of tomorrow resonated with hope and inspiration today as elementary students from Dallas, Houston, and Chicago took the stage for the final rounds of Foley & Lardner LLP's Annual MLK Jr.

ManaMed LLC, a global leader in orthopedic mobility and post-operative rehabilitation equipment, is thrilled to announce the launch of three groundbreaking products designed to enhance patient care.

In 2024, there were numerous trials and a few regulatory moves related to advancements in lipid management for the prevention ...

Based on the “compelling” Phase 3 trial data generated from Arrowhead’s plozasiran, an RNA interference therapeutic targeting apolipoprotein C-III in familial chylomicronemia syndrome ...

The analysts pointed out the ongoing regulatory review of Arrowhead's leading program, APOC3 targeting siRNA plozasiran, and potential benefits from the recent FDA approval of a similar drug ...

The analysts highlighted the ongoing regulatory review of Arrowhead's leading program, APOC3 targeting siRNA plozasiran, noting its potential benefits from the recent FDA approval of a similar drug, ...

The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome ...